Figure 2 from Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K–Mutant Advanced or Metastatic Melanoma

PFS and OS for encorafenib plus binimetinib or encorafenib vs. vemurafenib by (A and B) ERBB2 expression level and (C and D) PI3K pathway mutation status. Bini, binimetinib; BM, biomarker; Enco, encorafenib; Vemu, vemurafenib.